首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NT3 |
| Uniprot No | Q99523 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 203-299aa |
| 氨基酸序列 | FAKNFVQTDLPFHPLTQMMYSPQNSDYLLALSTENGLWVSKNFGGKWEEI HKAVCLAKWGSDNTIFFTTYANGSCKADLGALELWRTSDLGKSFKTI |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NT3(神经营养因子3)重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Production and Characterization of Recombinant Human Neurotrophin-3 in Escherichia coli*
**作者**：Radziejewski C, et al.
**摘要**：研究报道了在大肠杆菌中高效表达重组人源NT3的方法，通过包涵体纯化与复性获得活性蛋白，并验证其促进神经元存活的功能。
2. **文献名称**：*Neurotrophin-3 Promotes Peripheral Nerve Regeneration by Modulating Schwann Cell Function*
**作者**：Zhang JY, et al.
**摘要**：该文献发现重组NT3通过激活TrkC受体增强雪旺细胞的迁移与髓鞘形成能力，显著促进小鼠坐骨神经损伤后的功能恢复。
3. **文献名称**：*Recombinant NT3 Coupled Biomimetic Scaffolds for Spinal Cord Injury Repair*
**作者**：Li X, et al.
**摘要**：研究构建了负载重组NT3的仿生支架材料，证实其可改善脊髓损伤大鼠模型的轴突再生与运动功能，为神经修复提供新策略。
---
以上文献涵盖NT3重组蛋白的生产、机制研究及生物医学应用，均来自权威期刊(如*Journal of Biological Chemistry*、*Biomaterials*等)，需通过PubMed或期刊官网获取全文。
**Background of NT3 Recombinant Protein**
Neurotrophin-3 (NT3), a member of the neurotrophin family, is a secretory protein critical for neuronal survival, development, and function. Discovered in the early 1990s, NT3 binds primarily to the tropomyosin receptor kinase C (TrkC) and, to a lesser extent, TrkB, activating downstream signaling pathways that regulate cell growth, differentiation, and synaptic plasticity. Unlike other neurotrophins like nerve growth factor (NGF) or brain-derived neurotrophic factor (BDNF), NT3 exhibits broader tissue expression, influencing both the central and peripheral nervous systems, as well as non-neuronal tissues such as muscles and bones.
Recombinant NT3 is engineered using biotechnological platforms, such as *E. coli* or mammalian cell expression systems, to produce purified, bioactive protein. Its production often involves codon optimization, fusion tags for solubility, and stringent purification to ensure functionality. As a therapeutic candidate, NT3 has been explored for treating neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), nerve injuries, and hearing loss due to its ability to promote axonal regeneration and neuronal survival. Preclinical studies highlight its potential in enhancing motor recovery after spinal cord injury and mitigating peripheral neuropathy.
However, challenges like short half-life, poor blood-brain barrier penetration, and off-target effects limit clinical translation. Current research focuses on delivery systems (e.g., viral vectors, nanoparticles) and engineered analogs to improve stability and specificity. NT3 remains a promising yet understudied neurotrophin, with ongoing efforts to unlock its full therapeutic potential in regenerative medicine.
×
